BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder.

@article{Morelli2007BXL628AV,
  title={BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder.},
  author={Annamaria Morelli and Linda 4 Vignozzi and S. Filippi and Gabriella Barbara Vannelli and Stefano Ambrosini and Rosa Mancina and Clara Crescioli and Silvia Donati and Benedetta Fibbi and Enrico Colli and L. Adorini and Mario Maggi},
  journal={The Prostate},
  year={2007},
  volume={67 3},
  pages={234-47}
}
BACKGROUND BXL-628 is a calcitriol analog shown to decrease prostate growth in preclinical and clinical studies. BPH symptoms are generated not only by prostate overgrowth but also by bladder overactivity, resulting from an increased RhoA/Rho-kinase signaling. Because bladder smooth muscle cells express VDR, we studied effects of BXL-628 on this pathway. METHODS RhoA and Rho-kinase gene expression and functional activity were studied in rat and human bladder smooth muscle by real-time RT-PCR… CONTINUE READING
17 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…